Northwestern Medicine Selects Tempus to Expand Genomic Testing

January 12, 2026

Collaboration will focus on the oncology patient population

CHICAGO--(BUSINESS WIRE)--Jan. 12, 2026-- Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding of their unique cancer, enabling clinicians to deploy tailored, effective treatments.

"The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage cancers," said Dr Howard Chrisman, President and CEO of Northwestern Memorial HealthCare. "The data generated from this approach will allow us to rapidly adopt novel treatments and facilitate the design of innovative clinical trials aimed at developing personalized cancer treatments."

Northwestern Medicine provides comprehensive cancer care, including state-of-the-art therapies and clinical trials. The health system is home to The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network (NCCN).

"This collaboration will deliver on our shared mission of driving the field of cancer testing forward by bringing the benefits of genomic testing to as broad a population as possible," said Eric Lefkofsky, Founder and CEO of Tempus. "With one of the industry's most comprehensive genomic portfolios and the operational infrastructure to support broad adoption, we look forward to supporting Northwestern Medicine in delivering more precise, personalized cancer care for their patients."

As part of the collaboration, Tempus will offer NM access to its genomic testing including solid tissue, DNA and RNA profiling, liquid biopsy, minimal residual disease (MRD) and more.

About Northwestern Medicine

To learn more about Northwestern Medicine, please visit NM.org.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus' portfolio of diagnostics and its capabilities for customers and the collaboration with Northwestern Medicine. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260112379072/en/

Erin Carron
media@tempus.com

Source: Tempus AI, Inc.